This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

4 Biotech Stocks Under $10 Making Big Moves

Ziopharm Oncology

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Ziopharm Oncology (ZIOP - Get Report) is a biopharmaceutical company engaged in the development and commercialization of small molecule and synthetic biology approaches to new cancer therapies. This stock is trading up 13.5% to $1.84 in recent trading.

Today's Range: $1.70-$1.86

52-Week Range: $1.49-$6.33

Volume: 2.98 million

Three-Month Average Volume: 2.12 million

Shares of ZIOP are soaring higher here after the company reported encouraging results from a preclinical trial of cancer therapy Ad-RTS-MiL-12. The drug is designed to enable the controlled delivery of a protein important for immune response to cancer.

From a technical perspective, ZIOP is gapping sharply higher here off extremely oversold territory with heavy upside volume. This stock recently gapped down big from over $5 to around $1.75 with heavy downside volume. Following that gap, shares of ZIOP went on to hit its recent 52-week low of $1.49. That gap down pushed shares of ZIOP into extremely oversold territory, since the stock's relative strength index dipped below 30. Shares of ZIOP are now quickly moving within range of triggering a major breakout trade. That trade will hit if ZIOP manages to take out its gap down day high of $2.11 with high volume.

Traders should now look for long-biased trades in ZIOP as long as it's trending above today's low of $1.70, and then once it sustains a move or close above that gap down day high of $2.11 with volume that hits near or above 2.12 million shares. If that breakout triggers soon, then ZIOP will set up to re-fill some of its previous gap down zone from late March that started just above $5.
4 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
ZIOP $5.58 2.20%
ACRX $3.47 0.00%
GALE $0.73 8.80%
ONTY $1.06 0.00%
AAPL $95.03 0.04%


Chart of I:DJI
DOW 16,030.61 +16.23 0.10%
S&P 500 1,863.83 +11.62 0.63%
NASDAQ 4,317.0120 +48.2490 1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs